Cormorant Asset Management’s Kura Oncology KURA Stock Holding History

Cormorant Asset Management’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-650,000	Closed	-$21.2M	–	122
2020 Q4	$21.2M	Buy	650,000 +150,000	+30%	+$5.27M	0.51%	47
2020 Q3	$15.3M	Sell	500,000 -200,000	-29%	-$4.42M	0.59%	45
2020 Q2	$11.4M	Sell	700,000 -100,000	-13%	-$1.44M	0.44%	55
2020 Q1	$7.96M	Sell	800,000 -200,000	-20%	-$2.29M	0.37%	53
2019 Q4	$13.8M	Sell	1,000,000 -231,500	-19%	-$3.43M	0.55%	46
2019 Q3	$18.7M	Sell	1,231,500 -168,500	-12%	-$3M	1.14%	31
2019 Q2	$27.6M	Hold	1,400,000	–	–	1.58%	22
2019 Q1	$23.2M	Buy	1,400,000 +850,000	+155%	+$13.1M	1.57%	24
2018 Q4	$7.72M	Buy	+550,000	New	+$7.29M	0.63%	42

Other funds holding KURA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cormorant Asset Management's KURA Position: Q1 2021 in Review

Cormorant Asset Management sold out of Kura Oncology (KURA) in Q1 2021, closing a stake of 650,000 shares — an estimated $21.2M sold.

Cormorant Asset Management first reported a position in KURA in Q4 2018 and held it in 9 quarters. The position peaked at $27.6M in Q2 2019. 171 funds tracked by Wall St. Rank hold KURA as of Q1 2021.

Cormorant Asset Management reported no remaining Kura Oncology position as of Q1 2021 after selling out during the quarter.
Cormorant Asset Management sold 650,000 Kura Oncology shares in Q1 2021, an estimated $21.2M.
Cormorant Asset Management first reported a position in Kura Oncology in Q4 2018 and held it in 9 quarters.
Cormorant Asset Management's Kura Oncology position peaked at $27.6M in Q2 2019.
171 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2021.

Based on Cormorant Asset Management's 13F filing for Q1 2021, filed 17 May 2021.